ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Interferon-β-1b: a review of its use in multiple sclerosis. Plosker GL CNS Drugs. 2011 Jan; 25(1):67-88. PMID: 21128695. Abstract
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro. Müller M, Frese A, Nassenstein I, Hoppen M, Marziniak M, Ringelstein E B, Kim K S, Schäbitz W-R, Kraus J Mult Scler. 2012 Feb; 18(2):236-9. Epub 2011 Aug 15. PMID: 21844066. Abstract
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study Neurology. 2010 Jun 8; 74(23):1877-85. PMID: 20530324. Abstract
10 years of interferon beta-1b (Beta feron therapy. Kappos L, Hartung H-P J Neurol. 2005 Sep; 252 Suppl 3:iii1-iii2. PMID: 16170493. Abstract
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. Arnason BGW J Neurol. 2005 Sep; 252 Suppl 3:iii28-iii33. PMID: 16170497. Abstract
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr; 43(4):655-61. PMID: 8469318. Abstract
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, et al. Neurology. 2006 Oct 10; 67(7):1242-9. Epub 2006 Aug 16. PMID: 16914693. Abstract
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon(INCOMIN) Trial Study Group Lancet. 2002 Apr 27; 359(9316):1453-60. PMID: 11988242. Abstract
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, et al. Neurology. 2006 Apr 11; 66(7):1056-60. Epub 2006 Mar 01. PMID: 16510769. Abstract
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, et al. Lancet Neurol. 2009 Oct; 8(10):889-97. Epub 2009 Sep 02. PMID: 19729344. Abstract
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Prod'homme T, Zamvil SS Nat Med. 2008 Jun; 14(6):614-5. PMID: 18535577. Abstract
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov 7; 352(9139):1491-7. PMID: 9820296. Abstract
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS Neurology. 2004 Nov 23; 63(10):1788-95. PMID: 15557491. Abstract
Betaseron (Interferon Beta-1b) for SC Injection Bayer HealthCare Pharmaceuticals Inc. , May 2010 Accessed on 27 Mar 2012 from http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf..
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Barkhof F, Polman CH, Radue E-W, Kappos L, Freedman MS, Edan G, Hartung H-P, Miller DH, Montalbán X, Poppe P, et al. Arch Neurol. 2007 Sep; 64(9):1292-8. PMID: 17846268. Abstract
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH, Montalbán X, Barkhof F, Radü E-W, Metzig C, et al. Lancet Neurol. 2009 Nov; 8(11):987-97. Epub 2009 Sep 10. PMID: 19748319. Abstract
Interferon β-1b directly modulates human neural stem/progenitor cell fate. Arscott TW, Soltys J, Knight J, Mao-Draayer Y Brain Res. 2011 Sep 21; 1413:1-8. Epub 2011 Jul 23. PMID: 21855056. Abstract
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. Muraro PA, Leist T, Bielekova B, McFarland HF J Neuroimmunol. 2000 Nov 1; 111(1-2):186-94. PMID: 11063837. Abstract
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Jensen J, Krakauer M, Sellebjerg F Cytokine. 2005 Jan 7; 29(1):24-30. PMID: 15579375. Abstract
Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis. Haghjooy Javanmard S, Saadatnia M M, Homayouni V V, Nikoogoftar M M, Maghzi AH, Etemadifar M, Chaitanya VG, McGee JC, Minagar A, Alexander SJ Front Biosci (Elite Ed). 2012; 4:1368-74. PMID: 22201961. Abstract
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD Neurology. 2009 Jun 9; 72(23):1976-83. Epub 2009 Mar 11. PMID: 19279320. Abstract
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting or Clinically Isolated Forms of Multiple Sclerosis Using 3 Tesla MRI With Triple-dose Gadolinium ClinicalTrials.gov, 6 May 2010 Accessed on 21 Mar 2012 from http://clinicaltrials.gov/show/NCT00176592.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients ClinicalTrials.gov, 18 Dec 2008 Accessed on 21 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00099502.
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H, European(EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advis, North American(NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Neurology. 2004 Nov 23; 63(10):1779-87. PMID: 15557490. Abstract
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Paty DW, Li DK Neurology. 1993 Apr; 43(4):662-7. PMID: 8469319. Abstract
Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995 Jul; 45(7):1277-85. PMID: 7617182. Abstract
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, et al. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-287. Epub 2011 Dec 21. PMID: 22193561. Abstract
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis ClinicalTrials.gov, 27 Aug 2010 Accessed on 26 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00206635.
Interferon-beta1b for the treatment of multiple sclerosis. Lam S, Wang S, Gottesman M Expert Opin Drug Metab Toxicol. 2008 Aug; 4(8):1111-7. PMID: 18680445. Abstract
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, et al. J Neurol. 2008 Sep; 255(9):1315-23. Epub 2008 Sep 25. PMID: 18825438. Abstract
Optimizing IFN Beta - 1B Dose (Optims) ClinicalTrials.gov, 11 May 2007 Accessed on 27 Mar 2012 from http://clinicaltrials.gov/ct2/show/NCT00473213?term=OPTIMS&rank=2.
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Etemadifar M, Janghorbani M, Shaygannejad V Acta Neurol Scand. 2006 May; 113(5):283-7. PMID: 16629762. Abstract
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC J Interferon Res. 1993 Oct; 13(5):333-40. PMID: 8301153. Abstract
Multiple sclerosis: pathogenesis and treatment. Loma I, Heyman R Curr Neuropharmacol. 2011 Sep; 9(3):409-16. PMID: 22379455. Abstract
Zist Daru, ZIFERON Zist Daru, 2010 Accessed on 28 Mar 2012 from http://www.zistdaru.ir/01.html.. Note: Page shows “ZIFERON” as trade name for interferon beta-1b
Iran mass produces MS drug Ziferon PRESSTV, 18 Sep 2010 Accessed on 28 Mar 2012 from http://www.presstv.ir/detail/143010.html.
Berlex continues legal challenge to FDA over MS drug. Glaser V Nat Biotechnol. 1996 Jul; 14(7):811-2. PMID: 9630997. Abstract
Interferon beta-1b PrescriptionDrug-Info.com, 26 Jan 2012 Accessed on 28 Mar 2012 from http://www.prescriptiondrug-info.com/drug_details.asp?title=Extavia&page=1008148&ad=true.
Extavia Prescribing Information Novartis, Aug 2009 Accessed on 28 Mar 2012 from http://www.pharma.us.novartis.com/product/pi/pdf/extavia.pdf.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy? Zimmermann O, Rodewald C, Radermacher M, Vetter M, Wiehe JM, Bienek-Ziolkowski M, Hombach V, Torzewski J J Card Fail. 2010 Apr; 16(4):348-56. Epub 2010 Feb 07. PMID: 20350703. Abstract
Interferon-beta(1b) treatment in neuromyelitis optica. Tanaka M, Tanaka K, Komori M Eur Neurol. 2009; 62(3):167-70. Epub 2009 Jul 07. PMID: 19590215. Abstract
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL Ann Neurol. 1996 Dec; 40(6):846-52. PMID: 9007089. Abstract
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. Stuve O, Chabot S, Jung SS, Williams G, Yong VW J Neuroimmunol. 1997 Dec; 80(1-2):38-46. PMID: 9413258. Abstract
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, et al. Neurology. 1999 Oct 22; 53(7):1402-8. PMID: 10534242. Abstract
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D Neurology. 2003 Jan 14; 60(1):52-7. PMID: 12525717. Abstract
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzalez-Toledo E, Minagar A Mult Scler. 2010 Jul; 16(7):801-9. PMID: 20621951. Abstract
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen H-J, Zettl UK Pharmacogenomics. 2010 Feb; 11(2):147-61. PMID: 20136355. Abstract
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, Bartolome M, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R, HHV-6 and Multiple Sclerosis Study Group Eur J Neurol. 2011 Aug; 18(8):1027-35. Epub 2011 Apr 25. PMID: 21518144. Abstract
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement. Tamura S, Warabi Y, Matsubara S J Clin Pharm Ther. 2012 May 30. PMID: 22642738. Abstract
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis Mountain View Pharmaceuticals, 11 Jun 2012 Accessed on 12 Jun 2012 from http://www.mvpharm.com/Documents/MVP%20Receives%20European%20Patent%20on%20Long-Acting%20MS%20Drug%20June%2011,%202012.pdf.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription. Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Maghzi A H, Fatehi F Acta Med Iran. 2012; 50(2):97-100. PMID: 22359077. Abstract
Editors' Pick Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H Pharmacogenomics J. 2012 Jun 19. PMID: 22711062. Abstract 1 member recommends
Plasma ubiquitin?proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b. Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander SJ, Gonzalez-Toledo E, Albitar M Neurol Res. 2012 Jun 16. PMID: 22709658. Abstract
Interferon beta for secondary progressive multiple sclerosis. La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G Cochrane Database Syst Rev. 2012; 1:CD005181. PMID: 22258960. Abstract
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting Market Watch, The Wall Street Journal, 16 Jul 2012 Accessed on 16 Jul 2012 from http://www.marketwatch.com/story/enzon-presents-pre-clinical-data-on-controlled-release-of-pegylated-interferon-beta-1b-and-pegylated-anti-tnf-a-antibody-fragment-at-the-controlled-release-society-annual-meeting-2012-07-16.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A Eur J Clin Pharmacol. 2012 Apr; 68(4):441-8. Epub 2011 Nov 05. PMID: 22057838. Abstract
Editors' Pick Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, Desimone TM, et al. Neurology. 2012 Apr 24; 78(17):1315-22. Epub 2012 Apr 11. PMID: 22496198. Abstract
Editors' Pick Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Shirani A, Zhao Y, Karim M E, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H JAMA. 2012 Jul 18; 308(3):247-56. Epub 1969 Dec 31. PMID: 22797642. Abstract
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States. Pan F, Goh J W, Cutter G, Su W, Pleimes D, Wang C Clin Ther. 2012 Aug 17. PMID: 22906738. Abstract
Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Lu E, Wang B W, Guimond C, Synnes A, Sadovnick D, Tremlett H Neurology. 2012 Aug 29. PMID: 22933738. Abstract
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients. Skrzipek S, Vogelgesang A, Bröker BM, Dressel A Mult Scler. 2012 May; 18(5):674-8. Epub 2011 Oct 24. PMID: 22025329. Abstract
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. Khan O, Bao F, Shah M, Caon C, Tselis A, Bailey R, Silverman B, Zak I J Neurol Sci. 2012 Jan 15; 312(1-2):7-12. Epub 2011 Sep 13. PMID: 21920559. Abstract
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study. Jacques F, Gaboury I, Christie S, Grand'maison F Mult Scler Int. 2012; 2012:935921. Epub 2012 Aug 15. PMID: 22966460. Abstract
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Hellwig K, Haghikia A, Rockhoff M, Gold R Ther Adv Neurol Disord. 2012 Sep; 5(5):247-53. PMID: 22973421. Abstract
Editors' Pick Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan JV, Miao EA, Shinohara ML Sci Signal. 2012 May 22; 5(225):ra38. PMID: 22623753. Abstract
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA Curr Med Res Opin. 2012 May; 28(5):767-80. Epub 2012 Apr 24. PMID: 22462530. Abstract
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. Dhib-Jalbut S, Sumandeep S, Valenzuela R, Ito K, Patel P, Rametta M J Neuroimmunol. 2012 Sep 18. PMID: 22999187. Abstract
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study. Portaccio E, Stromillo M, Goretti B, Hakiki B, Giorgio A, Rossi F, De Leucio A, De Stefano N, Amato MP Eur J Neurol. 2012 Oct 11. PMID: 23057658. Abstract
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, et al. BMJ Open. 2012; 2(6). PMID: 23204140. Abstract
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study. Meca-Lallana JE, Balseiro JJ, Lacruz F, Guijarro C, Sanchez O, Cano A, Costa-Frossard L, Hernández-Clares R, Sanchez-De la Rosa R, Escala Study Group J Neurol Sci. 2012 Apr 15; 315(1-2):123-8. Epub 2011 Nov 30. PMID: 22133480. Abstract
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity. Barnard JG, Babcock K, Carpenter JF J Pharm Sci. 2012 Dec 11. PMID: 23233295. Abstract
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr K-M, Vedeler CA Acta Neurol Scand Suppl. 2012(195):84-9. PMID: 23278662. Abstract
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy. Ikeda K, Okamoto T, Yamamura T, Ohsawa I, Furutera R, Murata M Rinsho Shinkeigaku. 2013; 53(1):19-23. PMID: 23328061. Abstract
Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease. Pauwels I, Cosemans L, Boonen S, Dubois B, Goris A Mult Scler. 2013 Jan 16. PMID: 23325590. Abstract
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice. Kijanka G, Jiskoot W, Schellekens H, Brinks V Pharm Res. 2013 Jan 30. Epub 2013 Jan 30. PMID: 23361590. Abstract
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis. J Med Econ. 2013 Feb 7. PMID: 23391123. Abstract
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy. Wallbach M, Gröne HJ, Kitze B, Müller GA, Koziolek MJ Am J Kidney Dis. 2013 Jan 31. PMID: 23375818. Abstract
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J J Neurol Sci. 2012 Aug 15; 319(1-2):18-23. Epub 2012 Jun 05. PMID: 22676847. Abstract
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Romeo M, Martinelli-Boneschi F, Rodegher M, Esposito F, Martinelli V, Comi G, San Raffaele Multiple Sclerosis Clinical Group Eur J Neurol. 2013 Feb 20. PMID: 23425504. Abstract
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Orvain C, Augusto J-F, Besson V, Marc G, Coppo P, Subra J-F, Sayegh J Int Urol Nephrol. 2013 Feb 24. Epub 2013 Feb 24. PMID: 23435773. Abstract
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status Biogen Idec, 18 Mar 2013 Accessed on 21 Mar 2013 from http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1797077.
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC Front Immunol. 2013; 4:63. Epub 2013 Mar 13. PMID: 23493880. Abstract
Editors' Pick The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, Liew D, Butzkueven H, Slee M, Slee M PLoS One. 2013; 8(3):e59694. Epub 2013 Mar 19. PMID: 23527252. Abstract
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis. Stojanovic I, Vojinovic S, Ljubisavljevic S, Pavlovic R, Basic J, Pavlovic D, Ilic A, Cvetkovic T, Stukalov M J Neurol Sci. 2012 Dec 15; 323(1-2):187-92. Epub 2012 Sep 28. PMID: 23026532. Abstract
Interferon β for secondary progressive multiple sclerosis: a systematic review. La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, Filippini G J Neurol Neurosurg Psychiatry. 2013 Apr; 84(4):420-6. Epub 2012 Sep 05. PMID: 22952326. Abstract
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A Mult Scler. 2013 May 7. PMID: 23652214. Abstract
Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies. Gobbi C, Zecca C, Linnebank M, Müller S, You X, Meier R, Borter E, Traber M Eur Neurol. 2013 May 14; 70(1):35-41. Epub 2013 May 14. PMID: 23689307. Abstract
Effects of Interferon β-1a and Interferon β-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study. Stępień A, Chalimoniuk M, Lubina-Dąbrowska N, Chrapusta SJ, Galbo H, Langfort J Neuroimmunomodulation. 2013 May 24; 20(4):213-222. Epub 2013 May 24. PMID: 23711618. Abstract
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. Hartung H-P, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, et al. JAMA Neurol. 2013 Jun 3:1-5. PMID: 23732754. Abstract
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G, Giovane C D, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G Cochrane Database Syst Rev. 2013 Jun 6; 6:CD008933. PMID: 23744561. Abstract
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study. Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F, REFORMS Study Group BMC Neurol. 2012; 12:154. Epub 2012 Dec 06. PMID: 23216674. Abstract
RNF and Betaseron® Tolerability Study (REFORMS) ClinicalTrials.gov, 8 Sep 2010 Accessed on 20 Jun 2013 from http://www.clinicaltrials.gov/ct2/show/NCT00428584.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators. Peelen E, Thewissen M, Knippenberg S, Smolders J, Muris A-H, Menheere P, Tervaert CJW, Hupperts R, Damoiseaux J J Neuroimmunol. 2013 May 15; 258(1-2):77-84. Epub 2013 Mar 19. PMID: 23517930. Abstract
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis. Kim Y J, Lee H Y, Lee J Y, Yoon T Y Int J Dermatol. 2013 Jun 20. PMID: 23786157. Abstract
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Nagtegaal G J, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung H-P, Miller D, Montalban X, Kappos L, Edan G, et al. Mult Scler. 2013 Jul 10. PMID: 23842212. Abstract
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b]. Zhang X, Zhang Q, Shi X, Yin R, Zhang Z, Hou X Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jul; 29(7):751-3. PMID: 23837989. Abstract
Editors' Pick An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL Sci Transl Med. 2012 Sep 26; 4(153):153ra131. PMID: 23019656. Abstract
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CRG, Zecca C BMC Neurol. 2013; 13:101. Epub 2013 Aug 02. PMID: 23915113. Abstract
Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. Derkow K, Bauer JMJ, Hecker M, Paap BK, Thamilarasan M, Koczan D, Schott E, Deuschle K, Bellmann-Strobl J, Paul F, et al. PLoS One. 2013; 8(8):e70626. Epub 2013 Aug 12. PMID: 23950974. Abstract
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b. Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN J Interferon Cytokine Res. 2013 Aug 20. PMID: 23962003. Abstract
Editors' Pick A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E J Clin Pharm Ther. 2013 Aug 20. PMID: 23957759. Abstract
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V BMC Neurol. 2013 Sep 6; 13(1):117. Epub 2013 Sep 06. PMID: 24011220. Abstract
Editors' Pick Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla A, Karkare SU, Balderston McGuiness C, Korn JR Curr Med Res Opin. 2013 Oct 1. Epub 1969 Dec 31. PMID: 24059944. Abstract
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW BMC Neurol. 2013 Oct 4; 13(1):138. Epub 2013 Oct 04. PMID: 24093542. Abstract
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review. Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JBB, Carneiro DSD, Carvalho MJ, Claudino R, Comini-Frota ER, et al. CNS Drugs. 2013 Oct 10. PMID: 24114585. Abstract
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients. Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D Cardiovasc Ther. 2013 Oct 1. PMID: 24119301. Abstract
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM, Johnson BH, Wenten M, Watson C Clin Ther. 2013 Oct; 35(10):1501-12. PMID: 24139422. Abstract
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung H-P, Miller D, Barkhof F, Herrmann J, Lanius V, et al. J Neurol Neurosurg Psychiatry. 2013 Nov 11. PMID: 24218527. Abstract
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Boeru G, Milanov I, De Robertis F, Kozubski W, Lang M, Rojas-Farreras S, Tomlinson M Med Devices (Auckl). 2013; 6:175-184. Epub 2013 Nov 15. PMID: 24255602. Abstract
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D Curr Med Res Opin. 2013 Dec 5. PMID: 24289170. Abstract
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report. Sahraian M A, Naser Moghadasi A, Owji M, Maboudi M, Kosari F, McGee JC, Minagar A J Med Case Rep. 2013 Dec 13; 7(1):270. Epub 2013 Dec 13. PMID: 24330713. Abstract
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon. Zare N, Zarkesh-Esfahani S H, Gharagozloo M, Shaygannejad V J Korean Med Sci. 2013 Dec; 28(12):1801-6. Epub 2013 Nov 26. PMID: 24339712. Abstract
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. Rot U, Ledinek A H Clin Neurol Neurosurg. 2013 Dec; 115 Suppl 1:S79-81. PMID: 24321162. Abstract
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr K-M Mult Scler. 2014 Jan 16. PMID: 24436455. Abstract 1 member recommends
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study. Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, et al. Eur Neurol. 2014 Jan 21; 71(3-4):173-179. Epub 2014 Jan 21. PMID: 24457374. Abstract
Editors' Pick Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. Ascherio A, Munger KL, White R, Köchert K, Simon K C, Polman CH, Freedman MS, Hartung H-P, Miller DH, Montalbán X, et al. JAMA Neurol. 2014 Jan 20. PMID: 24445558. Abstract
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Fox RJ, Salter AR, Tyry T, Sun J, You X, Laforet G, Campagnolo D Int J MS Care. 2013 Winter; 15(4):194-201. PMID: 24453783. Abstract
Relationship between disease-modifying therapy and depression in multiple sclerosis. Kirzinger SS, Jones J, Siegwald A, Crush A B Int J MS Care. 2013 Fall; 15(3):107-12. PMID: 24453772. Abstract
Editors' Pick Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, Balderston McGuiness C, Korn JR PLoS One. 2014; 9(2):e88472. Epub 2014 Feb 06. PMID: 24516663. Abstract
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, et al. Mult Scler. 2014 Feb 10. PMID: 24515732. Abstract
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, Jeffery D, Kappos L, Filippi M, Beckmann K, et al. J Neurol. 2013 Jul; 260(7):1838-45. Epub 2013 Mar 17. PMID: 23504050. Abstract
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta. Zecca C, Riccitelli GC, Calabrese P, Pravatà E, Candrian U, Guttmann CRG, Gobbi C BMC Neurol. 2014; 14(1):38. Epub 2014 Feb 28. PMID: 24576156. Abstract
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs. Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick DA, Traboulsee A, Tremlett H CNS Drugs. 2014 Mar 19. PMID: 24643915. Abstract
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R Exp Neurol. 2014 Apr 13. PMID: 24731948. Abstract
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008. Tsai C-P, Lee C T-C Clin Drug Investig. 2013 Jul 17. PMID: 23861171. Abstract
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. Menzin J, Caon C, Nichols C, White L A, Friedman M, Pill MW J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S24-40. PMID: 23383731. Abstract
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Kulakova OG, Tsareva E Y, Lvovs D, Favorov AV, Boyko AN, Favorova OO Pharmacogenomics. 2014 Apr; 15(5):679-85. PMID: 24798724. Abstract
Interferon beta treatment of multiple sclerosis increases serum interleukin-7. Lundström W, Hermanrud C, Sjöstrand M, Brauner S, Wahren-Herlenius M, Olsson T, Karrenbauer V, Hillert J, Fogdell-Hahn A Mult Scler. 2014 May 12. PMID: 24821684. Abstract
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S J Neuroimmunol. 2014 Apr 24. PMID: 24814390. Abstract
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM, Albano JD, Rametta MJ BMJ Open. 2014; 4(5):e004536. PMID: 24821713. Abstract
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial. Mokhber N, Azarpazhooh A, Orouji E, Rao SM, Khorram B, Sahraian M A, Foroghipoor M, Gharavi M M, Kakhi S, Nikkhah K, et al. J Neurol Sci. 2014 Feb 4. PMID: 24841321. Abstract
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, et al. BMC Neurol. 2014 May 26; 14(1):114. Epub 2014 May 26. PMID: 24884599. Abstract
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients. O'Connell KE, Mok T, Sweeney B, Ryan AM, Dev KK Autoimmunity. 2014 Jun 30:1-7. PMID: 24974887. Abstract
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014; 114(5):65-9. PMID: 24988963. Abstract
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis. Hou Y, Ryu C H, Jun J A, Kim S M, Jeong C H, Jeun S-S J Neuroimmunol. 2014 Jun 20. PMID: 25005115. Abstract
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, Balderston McGuiness C, Korn JR J Med Econ. 2014 Jul 23:1-12. PMID: 25019581. Abstract
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A Cochrane Database Syst Rev. 2014; 7:CD009333. Epub 1969 Dec 31. PMID: 25062935. Abstract
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo M I, Garcia-Martinez A, Arias-Leal A M, Casanova I, Arroyo R, Alvarez-Lafuente R PLoS One. 2014; 9(8):e104836. Epub 2014 Aug 11. PMID: 25110949. Abstract
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis. Trenova AG, Slavov GS, Manova MG, Kostadinova II Arch Med Res. 2014 Aug 14. PMID: 25130430. Abstract
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study. Galuppo M, Giacoppo S, Sessa E, Bramanti P, Mazzon E J Neurol Sci. 2014 Jul 30. PMID: 25115502. Abstract
EU regulator warns on possible MS drugs side effects Reuters, 20 Aug 2014 Accessed on 25 Aug 2014 from http://www.reuters.com/article/2014/08/20/ms-drugs-sideeffects-idUSL5N0QQ3T620140820.
Pregnancy outcomes in patients exposed to interferon beta-1b. Romero RS, Lünzmann C, Bugge J-P J Neurol Neurosurg Psychiatry. 2014 Sep 2. PMID: 25185209. Abstract
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C BMJ Open. 2014; 4(1):e004073. PMID: 24441054. Abstract
Beta-Interferon, Glatiramer Acetate Cost-Effective in MS Hughes S, Medscape Medical News, 18 Sep 2014 Accessed on 23 Sep 2014 from http://www.medscape.com/viewarticle/831921.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. Balak D M, Hengstman G J, Hajdarbegovic E, van den Brule R J, Hupperts RMM, Thio H B BMC Neurol. 2013 Oct 16; 13(1):146. Epub 2013 Oct 16. PMID: 24131589. Abstract
Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, et al. Ann Clin Transl Neurol. 2014 Aug; 1(8):605-17. Epub 2014 Aug 22. PMID: 25285313. Abstract
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b. Yu L, Croze E, Yamaguchi KD, Tran T, Reder AT, Litvak V, Volkert MR J Interferon Cytokine Res. 2014 Oct 20. PMID: 25330068. Abstract
Long-Term Results Underscore Value of Early MS Treatment Melville NA, Medscape, 3 Nov 2014 Accessed on 4 Nov 2014 from http://www.medscape.com/viewarticle/834278.
Assessment of cancer risk with β-interferon treatment for multiple sclerosis. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H J Neurol Neurosurg Psychiatry. 2014 Mar 4. PMID: 24594506. Abstract
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. Freedman MS Ther Adv Neurol Disord. 2014 Nov; 7(6):279-88. PMID: 25371710. Abstract
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D J Neuroimmunol. 2014 Sep 15; 274(1-2):197-201. Epub 2014 Jul 15. PMID: 25064498. Abstract
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Beaber B E, Chi MD, Brara S M, Zhang J L, Langer-Gould AM Perm J. 2014 Winter; 18(1):9-13. PMID: 24626066. Abstract
Editors' Pick Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, et al. Mult Scler. 2014 Dec 5. PMID: 25480857. Abstract
Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, et al. J Immunol Res. 2014; 2014:961863. Epub 2014 Mar 26. PMID: 24741637. Abstract
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung H-P, Jarius S, Aktas O BMC Neurol. 2014 Dec 17; 14(1):247. Epub 2014 Dec 17. PMID: 25516429. Abstract
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A J Neurol Neurosurg Psychiatry. 2014 Dec 30. PMID: 25550414. Abstract
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. Prosperini L, Mancinelli C R, Pozzilli C, Grasso M G, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, et al. Eur Neurol. 2014 Jan 25; 71(5-6):135-143. Epub 2014 Jan 25. PMID: 24480868. Abstract
Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta. Mazzon E, Guarneri C, Giacoppo S, Rifici C, Tchernev G, Polimeni G, Wollina U Int J Immunopathol Pharmacol. 2014 Oct-Dec; 27(4):669-74. PMID: 25572749. Abstract
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome. Tso A-C, Tsao W-L, Chen C-Y, Yang C-F, Peng G-S Neurologist. 2015 Jan; 19(2):46-8. PMID: 25607332. Abstract
Editors' Pick IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity. Schubert RD, Hu Y, Kumar G, Szeto S, Abraham P, Winderl J, Guthridge JM, Pardo G, Dunn J, Steinman L, et al. J Immunol. 2015 Mar 1; 194(5):2110-2116. Epub 2015 Feb 02. PMID: 25646307. Abstract
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, et al. JAMA Neurol. 2015 Feb 9:1-10. PMID: 25665031. Abstract
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis. Harari D, Orr I, Rotkopf R, Baranzini SE, Schreiber G Hum Mol Genet. 2015 Feb 26. PMID: 25721402. Abstract
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H Mult Scler Relat Disord. 2015 Jan; 4(1):75-82. Epub 2014 Oct 07. PMID: 25787057. Abstract
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids. Rossi S, Motta C, Studer V, Boffa L, De Chiara V, Castelli M, Barbieri F, Buttari F, Monteleone F, Germani G, et al. CNS Neurosci Ther. 2014 May 19. PMID: 24837039. Abstract
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, et al. Lancet Neurol. 2015 Apr 1. PMID: 25841667. Abstract
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, et al. PLoS One. 2015; 10(4):e0123824. Epub 2015 Apr 13. PMID: 25867095. Abstract
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b) PR Newswire, 22 Apr 2015 Accessed on 28 Apr 2015 from http://www.prnewswire.com/news-releases/fda-accepts-filing-of-betaconnect-for-relapsing-remitting-multiple-sclerosis-patients-taking-betaseron-interferon-beta-1b-300070199.html.
Comparative efficacy of switching to natalizumab in active multiple sclerosis. Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, et al. Ann Clin Transl Neurol. 2015 Apr; 2(4):373-87. Epub 2015 Feb 27. PMID: 25909083. Abstract
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11) Edan G, Freedman M, Montalban X, Miller D, Hartung H, Hemmer B, Fox E, Barkhof F, Schippling S, Schulze A, et al., Neurology 2015 Apr; 84(14) Supplement P7.012 Accessed on 19 May 2015 from http://www.neurology.org/content/84/14_Supplement/P7.012.short?rss=1.
Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review. Faghihi G, Basiri A, Pourazizi M, Abtahi-Naeini B, Saffaei A J Res Pharm Pract. 2015 Apr-Jun; 4(2):99-103. PMID: 25984549. Abstract
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Piñol C Neurologia. 2015 May 11. PMID: 25976942. Abstract
Editors' Pick A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, et al. Ann Neurol. 2015 Apr 25. PMID: 25914168. Abstract
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C CNS Drugs. 2015 Jun 26. PMID: 26113055. Abstract
Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP J Interferon Cytokine Res. 2011 Mar; 31(3):337-44. Epub 2011 Jan 12. PMID: 21226608. Abstract
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D, Schmitz N, Kugler J PLoS One. 2015; 10(7):e0133279. Epub 2015 Jul 27. PMID: 26214805. Abstract
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients. Wostradowski T, Gudi V, Pul R, Gingele S, Lindquist JA, Stangel M, Lindquist S Clin Exp Immunol. 2015 Jul 25. PMID: 26212126. Abstract
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study. Lus G, Signoriello E, Maniscalco GT, Bonavita S, Signoriello S, Gallo C Eur J Neurol. 2015 Jul 26. PMID: 26212486. Abstract
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Hartung H-P, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, et al. J Neurol. 2015 Aug 5. Epub 2015 Aug 05. PMID: 26239222. Abstract
A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis. Gulati A, Bagnato F, Villoslada P, Velez de Mendizabal N CPT Pharmacometrics Syst Pharmacol. 2015 May; 4(5):295-304. Epub 2015 Apr 24. PMID: 26225255. Abstract
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis. Govindappa K, Sathish J, Park K, Kirkham J, Pirmohamed M Eur J Clin Pharmacol. 2015 Aug 14. Epub 2015 Aug 14. PMID: 26268445. Abstract
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells. Damiano S, Sasso A, De Felice B, Terrazzano G, Brescia Morra V, Carotenuto A, Orefice NS, Orefice G, Vacca G, Belfiore A, et al. Brain Res Bull. 2015 Sep 3; 118:1-6. PMID: 26327496. Abstract
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore G B, Marrosu M G, et al. Brain. 2015 Sep 11. PMID: 26362907. Abstract
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, et al. Mult Scler. 2015 Sep 11. PMID: 26362898. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment PR Newswire, 25 Sep 2015 Accessed on 29 Sep 2015 from http://www.prnewswire.com/news-releases/bayer-receives-fda-approval-for-betaconnect---first-and-only-electronic-autoinjector-in-relapsing-remitting-multiple-sclerosis-rrms-treatment-300149438.html.
Editors' Pick Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. Fitzgerald KC, Munger KL, Köchert K, Arnason BGW, Comi G, Cook S, Goodin DS, Filippi M, Hartung H-P, Jeffery DR, et al. JAMA Neurol. 2015 Oct 12:1-8. PMID: 26458124. Abstract
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Munger KL, Fitzgerald KC, Freedman MS, Hartung H-P, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue E-W, et al. Neurology. 2015 Oct 9. PMID: 26453645. Abstract
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities. Mehrpour M, Akhoundi FH, Delgosha M, Keyvani H, Motamed MR, Sheibani B, Meysamie A Neurologist. 2015 Oct; 20(4):57-60. PMID: 26468869. Abstract
Editors' Pick Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J Health Econ Rev. 2015 Dec; 5(1):30. Epub 2015 Oct 16. PMID: 26475277. Abstract
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Kvistad S, Myhr K-M, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, et al. Mult Scler. 2014 May 19. PMID: 24842958. Abstract
Effect of vitamin D on MS activity by disease-modifying therapy class. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167. Epub 2015 Oct 29. PMID: 26568968. Abstract
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV PLoS One. 2015; 10(11):e0143393. Epub 2015 Nov 23. PMID: 26600308. Abstract
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Ziemssen T, Sylvester L, Rametta M, Ross A P Neurol Ther. 2015 Dec; 4(2):125-36. Epub 2015 Oct 27. PMID: 26662362. Abstract
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development. Uçar İ, Ertekin T, Nisari M, Ceylan D, Al Ö, Ülger H Folia Morphol (Warsz). 2015 Dec 29. PMID: 26711647. Abstract
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'maison F, et al. Eur J Neurol. 2016 Jan 19. PMID: 26782663. Abstract
Drug Safety Labeling Changes US Food and Drug Administration, 13 Jan 2016 Accessed on 29 Jan 2016 from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm480758.htm.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X J Neuroimaging. 2016 Mar 2. PMID: 26935253. Abstract
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJA, Strijbis EMM, Steenwijk MD, Polman CH, Pouwels PJW, Barkhof F, Geurts JJG AJNR Am J Neuroradiol. 2016 Mar 10. PMID: 26965463. Abstract
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J, Chamoux C, Hammès F, Chicoye A PLoS One. 2016; 11(3):e0150703. Epub 2016 Mar 17. PMID: 26987055. Abstract
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis. Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani M P Mult Scler Relat Disord. 2016 Mar; 6:57-63. Epub 2016 Feb 02. PMID: 27063624. Abstract
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, et al. Pharmacogenomics J. 2016 Mar 22. PMID: 27001119. Abstract
